AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• AtriCure has a “Moderate Buy” consensus rating from 12 analysts: seven buys, four holds, and one strong buy. The average 12-month price target is approximately $49.89.
• The company reported quarterly earnings of $0.18 per share and revenue of $153.6 million, exceeding the $151.8 million consensus estimate. Analysts expect full-year 2026 earnings of about $0.29 per share.
• AtriCure shares opened at $48.35, near their 52-week high of $49.98, while institutional investors own 99.11% of the stock; insiders have sold approximately $2.15 million worth of shares over the past 90 days.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $49.8889.

Several research analysts have recently commented on ATRC shares. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $55.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a report on Tuesday, July 21st. Piper Sandler lifted their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday. Citigroup reiterated a "market outperform" rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, UBS Group dropped their price target on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,564 shares of the business's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Karl S. Dahlquist sold 9,370 shares of the company's stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the sale, the insider owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock worth $2,149,994 over the last 90 days. 4.00% of the stock is owned by insiders.

Institutional Investors Weigh In On AtriCure

Several hedge funds have recently made changes to their positions in the business. Amundi boosted its holdings in shares of AtriCure by 17.2% in the second quarter. Amundi now owns 264,854 shares of the medical device company's stock valued at $7,411,000 after acquiring an additional 38,922 shares in the last quarter. HighTower Advisors LLC purchased a new position in AtriCure during the second quarter worth about $238,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in AtriCure during the second quarter worth about $481,000. California State Teachers Retirement System lifted its position in AtriCure by 2,627.3% in the second quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company's stock valued at $45,745,000 after purchasing an additional 1,574,980 shares during the period. Finally, Three Seasons Wealth LLC acquired a new stake in AtriCure in the second quarter valued at about $200,000. Institutional investors and hedge funds own 99.11% of the company's stock.

AtriCure Price Performance

Shares of ATRC opened at $48.35 on Tuesday. The business's 50-day moving average is $38.29 and its two-hundred day moving average is $32.30. The company has a market capitalization of $2.46 billion, a P/E ratio of 230.25 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $49.98.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure will post 0.29 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source